Transplantation of Specific Human Astrocytes Promotes Functional
                    Recovery after Spinal Cord Injury by Davies, Stephen J. A. et al.
Transplantation of Specific Human Astrocytes Promotes
Functional Recovery after Spinal Cord Injury
Stephen J. A. Davies
1, Chung-Hsuan Shih
2, Mark Noble
2, Margot Mayer-Proschel
2, Jeannette E.
Davies
1*
., Christoph Proschel
2*
.
1Department of Neurosurgery, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, United States of America, 2Department of Biomedical
Genetics, Institute for Stem Cell and Regenerative Medicine, University of Rochester Medical Center, Rochester, New York, United States of America
Abstract
Repairing trauma to the central nervous system by replacement of glial support cells is an increasingly attractive therapeutic
strategy. We have focused on the less-studied replacement of astrocytes, the major support cell in the central nervous
system, by generating astrocytes from embryonic human glial precursor cells using two different astrocyte differentiation
inducing factors. The resulting astrocytes differed in expression of multiple proteins thought to either promote or inhibit
central nervous system homeostasis and regeneration. When transplanted into acute transection injuries of the adult rat
spinal cord, astrocytes generated by exposing human glial precursor cells to bone morphogenetic protein promoted
significant recovery of volitional foot placement, axonal growth and notably robust increases in neuronal survival in multiple
spinal cord laminae. In marked contrast, human glial precursor cells and astrocytes generated from these cells by exposure
to ciliary neurotrophic factor both failed to promote significant behavioral recovery or similarly robust neuronal survival and
support of axon growth at sites of injury. Our studies thus demonstrate functional differences between human astrocyte
populations and suggest that pre-differentiation of precursor cells into a specific astrocyte subtype is required to optimize
astrocyte replacement therapies. To our knowledge, this study is the first to show functional differences in ability to
promote repair of the injured adult central nervous system between two distinct subtypes of human astrocytes derived
from a common fetal glial precursor population. These findings are consistent with our previous studies of transplanting
specific subtypes of rodent glial precursor derived astrocytes into sites of spinal cord injury, and indicate a remarkable
conservation from rat to human of functional differences between astrocyte subtypes. In addition, our studies provide a
specific population of human astrocytes that appears to be particularly suitable for further development towards clinical
application in treating the traumatically injured or diseased human central nervous system.
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Introduction
The recognition that astrocyte dysfunction may play an
important role in a wide range of neurological disorders raises the
question of whether astrocyte transplantation could be of thera-
peutic value in treating the injured or diseased human central
nervous system (CNS). For example, it has long been known that
astrocytes within glial scar tissue contribute to the failure of axon
regeneration across sites of traumatic brain or spinal cord injury [1–
6]. A failure of normal astrocyte generation by CNS precursor cells
hasbeendiscovered to be a consequenceof themutations that cause
Vanishing White Matter leukodystrophy [7], and dysfunction of
astrocytes has also been suggested to be of importance in models of
amyotrophic lateral sclerosis [8], forebrain ischemic injury [9],
epileptic seizures [10], Huntington’s disease [11], tuberous sclerosis
[12] and Rett syndrome [13]. We therefore have proposed that
enhancing astrocyte function through transplantation of specific
subtypes of astrocytes derived from glial precursors will promote
repair and functional recovery after CNS injury [14].
There are a number of challenges inherent in the development
of astrocyte-based treatments for human disease. One of the most
important of these is the question of whether all astrocytes are
equivalent in their ability to promote repair, or whether specific
populations of astrocytes are more useful than others. While
previous studies had demonstrated a synergistic effect of BMP and
LIF on the astrocytic differentiation of human neural stem cells
[15], it remains unclear whether BMP and LIF induce distinct
types of astrocytes and if so, what the functional properties of these
astrocytes may be with respect to repairing CNS injuries. The
recent description of considerable astrocyte heterogeneity in the
human CNS raises the question whether distinct astrocytes can
also be derived from single populations of human glial precursors,
and more importantly whether different human astrocyte
populations exhibit distinct functional properties [16]. Further
challenges include the identification of signaling molecules that
promote the generation of beneficial populations of astrocytes,
identification of appropriate stem and/or progenitor cell popula-
tions that can be the source of such cells, and determination of
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17328whether there are situations in which it is more useful to transplant
astrocytes themselves rather than to transplant stem or progenitor
cells that might generate astrocytes in vivo in response to signals
present in the host environment.
We now show that astrocytes generated from the same
population of human fetal glial precursor cells, by exposure to
either bone morphogenetic protein (BMP) or ciliary neurotrophic
factor (CNTF), promote widely divergent outcomes with respect to
repairing the injured adult spinal cord. Transplantation of
astrocytes generated by exposure of human glial progenitor cells
(hGPCs) to BMP (hGDAs
BMP) promoted robust behavioral
recovery and multi-laminae protection of spinal cord neurons
following spinal cord injury (SCI), while transplantation of
undifferentiated hGPCs or astrocytes generated by hGPC
exposure to CNTF (hGDAs
CNTF) failed to provide such benefits.
These results provide a defined population of human astrocytes
suitable for further pre-clinical development for treatment of SCI,
and demonstrate that pre-differentiation into astrocytes prior to
transplantation provides a much greater functional recovery than
transplantation of precursor cells themselves. Our results also
underscore the importance of function-based analysis of astrocyte
diversity as a foundation for the development of astrocyte
transplantation-based therapies.
Results
Human glial precursors give rise to two distinct astrocyte
populations in vitro
As a first step towards determining whether human glial
progenitor cells (hGPCs) can generate functionally distinct
astrocyte populations, we exposed embryonic hGPCs isolated
from spinal cords of 9.5 week old abortuses to BMP or CNTF.
Both BMP and CNTF-induced astrocyte populations express
GFAP (Fig. 1 A–C), AQP4 and S100b (Fig. 1 D), three widely used
markers of astrocyte differentiation [17–22]. hGDAs
BMP also
expressed connexin 43 (CX43), glutamate transporter 1 (GLT-1),
AKAP12 and glia-derived neurotrophic factor (GDNF), all of
which are expressed in the astroglial lineage [23–25]. In contrast,
CNTF treatment did not induce expression of GLT-1, connexin
43, AKAP12, or GDNF. Instead, hGDAs
CNTF – but not
hGDAs
BMP – expressed several antigens expressed in astrocytes
generated in response to injury (Fig. 1 E and F), including the
transcription factor OLIG2 and the chondroitin sulphate proteo-
gylcans (CSPGs) phosphacan and CSPG4/NG2 [5,26–31]. Thus,
induction of differentiation of human spinal cord derived glial
precursors with BMP or CNTF induces the generation of two
phenotypically distinct astrocyte populations.
Transplant morphology
To test the functional properties of these distinct astrocyte
populations in vivo, hGDAs
BMP, hGDAs
CNTF or undifferentiated
hGPCs were transplanted into the injury site of adult Sprague-
Dawley rats that had received unilateral transections of the right-
side dorso-lateral funiculus (DLF), including the rubrospinal
pathway, at the C3/C4 intervertebral spinal cord level.
Serial section analysis of transplants using antibodies to human
mitochondria (hMito) showed that the majority of hGDA
BMP
transplants (4 out of 6) and half of the hGDA
CNTF transplants (3
out of 6) that under went histological analysis had robust survival
of hMito+ cells at 5 weeks post transplantation within dorsolateral
funiculus (DLF) injury sites. Surviving transplants spanned the
rostral to caudal extent of injury sites to effectively provide
continuous substrates for potential growth of host axons across
sites of injury. Qualitative assessment of transplant size showed
that all surviving hGDA
CNTF transplants were larger than
hGDA
BMP transplants in terms of both their rostral to caudal
and lateral to medial extents (Fig. 2 A–D).
We next found that hGDA
BMP grafted injury sites exhibited
higher densities of axons than hGDA
CNTF grafted injury sites. As
shown in figure 2, hGDA
BMP grafts contained many 200 kD
neurofilament+ axons (Fig. 2 A and E), while relatively few axons
were observed in hGDA
CNTF grafts (Fig. 2 B and F). Quantifi-
cation of neurofilament immuno-reactivity within hGDAs
BMP and
hGDAs
CNTF treated injury sites revealed that the injury centers of
hGDA
BMP treated spinal cords contained almost double the
density of NF+ axon profiles (1.91 fold more: average 14.79 units
2
+/2 3.05 st. dev.) than measured in hGDA
CNTF treated injury
centers (average 7.75 units
2 +/2 2.28 st. dev.; p=0.003). Notably
the profiles of the majority of NF+ axons, particularly within the
rostral and caudal margins of hGDA
BMP grafted injuries, were end
on to the transverse plane of section indicating that, as previously
observed for axons within spinal cord injury sites bridged with
rodent GDAs
BMP [14], these axons were aligned with the normal
rostral/caudal trajectory of the DLF white matter (Fig. 2 A and E).
hGDA migration and cell morphology
Analysis of the migration of transplanted hMito+ hGDAs
revealed similar patterns of distribution within spinal cord gray
matter. The highest densities of both types of hGDAs were
observed within laminae 4, 5 and 6 of gray matter directly
adjacent to sites of injury (Fig. 2 A–D). In contrast, relatively few
hMito+ hGDA cells of either type were observed within laminae 7,
8 and 9 (Fig. 2 A–D) directly adjacent to injury sites. No hMito+
cells of either type of hGDA were observed to have migrated
medially in either gray or white matter beyond the central canal
i.e. into the contra-lateral side of the spinal cord. Significantly, in
all hGDA treated cords analyzed, neither type of hGDA was found
in the contra-lateral side of the spinal cord or within gray matter
rostral or caudal to the injury site. Migration of hGDAs in white
matter was more extensive than in gray matter, with both types of
hGDAs showing extensive migration both rostral and caudal to
the injury site, with maximum rostral/caudal migration distances
of 3.24 mm/3.96 mm recorded for hGDAs
CNTF and 2.52 mm/
2.16 mm recorded for hGDAs
BMP respectively.
High power imaging of the centers of both types of hGDA grafts
showed comparable densities of hMito positive cell bodies and
processes that contained GFAP+ intermediate filaments (Fig. 3).
Similar densities of hGDAs
BMP and hGDAs
CNTF had migrated to
the pial surface of lateral funiculus white matter both rostral and
caudal to the injury site (Figs. 2 C and D; Fig. 4 A and B). The
distribution and density of hMito+ mitochondria within individual
hGDAs was sufficient to identify their cell bodies and show that
both types of hGDA often displayed similar typical astrocytic
‘‘stellate’’ arrangements of their processes within transplant
parenchyma, gray matter and white matter (Fig. 2 E and F,
Fig. 3 A and B, Fig. 4 C).
hGDAs
BMP promote locomotor recovery while hGDAs
CNTF
do not
Despite the similar ability of transplanted hGDAs
BMP and
hGDAs
CNTF to span the rostral to caudal extent of injury sites and
migrate into adjacent tissues, only hGDAs
BMP promoted locomo-
tor recovery following transplantation into the transected dorso-
lateral funiculus (DLF). This injury severs descending, supraspinal
axons and causes chronic deficits in both fore- and hind-limb
motor function [32], which can be detected by the grid-walk
behavioral test [33]. A similar average number of mistakes were
seen in each group at 3 days post injury/transplantation (Fig. 5 A).
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PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17328Figure 1. Generation of two distinct types of astrocytes from human glial precursors after treatment with BMP4 or CNTF. Both BMP
and CNTF promote the differentiation of hGPCs into GFAP-positive astrocytes expressing S100b but with otherwise distinct morphological and
antigenic phenotypes. hGDAs
BMP express lower levels of GFAP and exhibit a more compact morphology. hGDAs
CNTF have a more elongated
morphology and expressed high levels of GFAP. hGDAs
CNTF also expressed high levels of neurite-outgrowth inhibitory chondroitin sulfate
proteoglycans, phosphacan and CSPG4, as well as the transcription factor Olig2 - all of which have been found to be upregulated in glial scar
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BMP group improved from an average 7.760.7
mistakes per crossing to 4.760.8, and further improved by day 28
to only 2.460.2 mistakes, comparable to uninjured controls. By
comparison, by day 28 the untreated injury group and animals
receiving hGDAs
CNTF transplants made 6.760.5 and 6.560.5
mistakes respectively. The number of mistakes made by rats in the
hGDA
CNTF group was not significantly different from those in the
media-injected DLF injured control group and did not improve
statistically over time. Persistent survival of the transplant was not
required in order to obtain benefit after transplantation, as
behavioral recovery was as extensive in animals in which
transplanted cells were still present at 5 weeks as in those in
which no human cells were detected at this time point.
Pre-differentiation of hGPCs to hGDAs
BMP is required for
robust functional recovery
We next examined the question of whether the precursor cells
from which hGDAs
BMP were derived were also capable of
promoting behavioral recovery after DLF transection and found
that pre-differentiation of these precursor cells into astrocytes was
essential to promote significant functional recovery. Rats that
received hGDA
BMP transplants performed significantly better on
the grid-walk test than either the hGPC transplanted group or the
media-injected control injury group at all time points from 7 to 28
days post injury/transplantation (Fig. 5 B). The number of
mistakes made by the hGPC treated group was not different from
the injury control group at all post-injury time points and did not
improve statistically over time. Specifically, at 3 days after injury/
transplantation the average number of mistakes for each group
were 8.2+/21.3 (media-injected control injury), 7.9+/21.6
(hGPCs), and 8.2+/21.4 (9W-1 hGDAs
BMP), which are not
significantly different from each other (as also seen for 9W-2
hGDAs
BMP). However by day 7 the hGDA
BMP group showed a
robust improvement to 3.75+/21.5 mistakes, and by 28 days post
injury/transplantation, the last time point tested, the 9W-1
hGDA
BMP group made an average of only 3.0+/20.7 mistakes,
compared to 5.5+/21.0 and 5.1+/20.8 mistakes for hGPC
treated and control groups respectively (p,0.05, Fig. 5 B).
hGDAs
BMP are more effective at providing
neuroprotection than hGDAs
CNTF and hGPCs
Differences in behavioral recovery were mirrored by marked
differences in promotion of neuronal survival within ipsilateral
gray matter immediately adjacent to sites of injury (Fig. 6 and
Fig. 7) and even within rostral and caudal gray matter in which no
transplanted hGDAs
BMP were observed. Previous studies of
neuron survival by the Priestley lab have confirmed with toluidine
blue histochemistry that NeuN immuno-reactivity is a reliable
marker of neuron survival after spinal cord injury [34]. At 5 weeks
post injury/transplantation, NeuN+ neuron cell bodies were
counted in laminae 4 to 9 on the injured, right hand side of the
spinal cord (Tables 1 and 2). These regions of the spinal cord were
chosen because they are either post synaptic targets of the
corticospinal (laminae 3–7, dense terminations; laminae 8 and 9,
sparse terminations), rubrospinal (laminae 5–7), and raphe
(laminae 7–9) supra-spinal motor systems; contain interneurons,
propriospinal neurons (laminae 4–8), or commissural neurons
(lamina 8) involved in motor control; or primary motor neurons
(lamina 9) [35–39].
Significant improvements in neuronal survival in all laminae
studied were seen in a 1.8 mm length of spinal cord encompassing
the injury site of hGDA
BMP-treated animals. Combined neuron
counts for all laminae (4 to 9) showed that hGDA
BMP
transplantation promoted increases of 40% and 32%, in two
separate experiments, of surviving neurons compared to untreated
injured spinal cords (Fig. 7 A; Table 1), with significant increases
seen in all laminae. Analysis of a region closer to the site of injury,
through 750 mm of tissue spanning the injury center, revealed
notably robust increases in numbers of neurons for lamina 7 (35%
and 32%) and laminae 8 and 9 (70% and 54%) above control
injured cords (Fig. 7 B; Table 2). As with behavioral recovery,
continued graft survival was not required for promotion of
neuronal survival. Significant increases in neuron numbers were
not observed in lamina 4, 5, 6 adjacent to injury centers, despite
rescue of neurons more distal to the zone of injury; an outcome
most likely due to neuron loss resulting from direct trauma to these
laminae at time of injury.
Discussion
The present studies provide multiple novel findings relevant to
the development of astrocyte transplantation therapies for
treatment of the injured or diseased central nervous system. We
show that subpopulations of human astrocytes, generated by
activation of different signaling pathways in the same population
of human glial precursor cells, have markedly different effects
when transplanted into the injured spinal cord. hGDAs
BMP
provided extensive benefit, including robust protection of spinal
cord neurons, increased support of axon growth and locomotor
recovery. In contrast, transplantation of either undifferentiated
hGPCs or hGDAs
CNTF failed to provide significant benefits. The
major gains in behavioral recovery and neuronal survival
achieved by pre-differentiation of glial precursors to specific,
beneficial astrocytic cell types prior to transplantation stresses the
need to consider such manipulations as a critical component in
the optimization of stem/precursor cell transplantation based
therapies.
The development of astrocyte transplantation represents a new
avenue for the treatment of CNS injury, as contrasted with the
extensive research that has been conducted on replacement of
oligodendrocytes. Starting with transplants of human oligoden-
drocytes in the late 1980s [40], and more recently with populations
of human oligodendrocyte progenitor cells isolated from the
developing or adult CNS, or from human embryonic stem cells, it
has been possible to generate extensive myelination upon
transplantation into spinal cord injury or into congenital mouse
models of hypomyelination [41–48]. In contrast, much less is
known about the potential utility of astrocyte-based therapies.
Moreover, initial studies showed only modest benefits of astrocyte
transplantation for treatment of traumatic injury to the spinal cord
[49–53].
associated astrocytes. (A–C) Human GPCs grown in bFGF (A) were induced to differentiate into astrocytes using BMP-4 (B) or CNTF (C). Labeling with
anti-GFAP (Alexa-488) demonstrates that both BMP4 and CNTF induce differentiation of human glial precursors into GFAP-expressing astrocytes,
while Olig2 expression (Alexa-568) is repressed in hGDAs
BMP. Scale bar=50 mm. (D) RT-QPCR analysis of hGPC, hGDA
BMP and hGDA
CNTF populations
reveals induction of AQP4 and S100b in both hGDAs
BMP and hGDAs
CNTF. Induction of CX43, GLT1, AKAP12 and GDNF however are restricted to
hGDAs
BMP. Average fold change and SD of expression levels is shown for three independent experiments using 9W-1 hGPCs. (E and F) Phosphacan
and CSPG4 remain elevated in hGDAs
CNTF and are reduced in hGDAs
BMP derived from both 9W-1 (E) and 9W-2 (F) glial precursors. Mean relative
protein expression and SD from three independent experiments are shown. Values were normalized to b-actin and expression in hGPCs.
doi:10.1371/journal.pone.0017328.g001
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and work on oligodendrocyte and oligodendrocyte-precursor
replacement lies in the finding that differentiation of precursor
cells into a specific astrocyte subtype prior to transplantation
provides a much greater level of benefit than transplantation of the
precursor cells themselves. This is the opposite situation to that
reported in the oligodendrocyte lineage, for which a greater degree
of pre-transplant differentiation is associated with less effective
Figure 2. Human GDA graft survival and support of axon growth within spinal cord DLF injuries. Immuno-staining for human
mitochondrial marker (red channel) of histological cross sections at sites of injury revealed hGDAs
BMP (A, C, E) and hGDAs
CNTF (B, D, F) transplant
masses spanning the dorsal-ventral and lateral-medial margins of injury sites. Arrowheads in C and D indicate accumulations of hGDAs
BMP and
hGDAs
CNTF respectively at the pial surface of lateral funiculus white matter (see also Fig. 4 A, B). Co-labeling for neurofilament (NF: green) and human
mitochondrial marker (hMito: red) shows a markedly higher density of axons within hGDAs
BMP treated injury sites (A, E) compared to hGDAs
CNTF
treated injury sites (B, F). Greater numbers of NF+ axons within hGDAs
BMP transplants aligned with the normal rostral/caudal trajectory of DLF white
matter (E) compared to NF+ axons within hGDAs
CNTF transplants (F). Survival=5 weeks post injury/transplantation. Scale bars: A, B, C, D=200 mm; E,
F=100 mm.
doi:10.1371/journal.pone.0017328.g002
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is of potential use in astrocyte replacement in neurological
disorders such as ALS [56], our results demonstrate the
importance of determining whether direct transplantation of
astrocytes themselves provides greater benefit. In light of the
modest benefits obtained with transplantation of rodent astrocytes
isolated directly from the immature CNS [49–53], however, our
present and earlier studies [14,57] suggest that it is necessary
instead to transplant astrocytes generated from precursor cells in
vitro in order to optimize benefit.
Along with demonstrating the marked benefits from astrocyte
transplantation in experimental injuries of the spinal cord, our
studies also demonstrate that obtaining benefit may require
transplanting very specific populations of human astrocytes. The
significant difference in outcome achieved by transplantation of
hGDAs
BMP versus hGDAs
CNTF demonstrates clearly that not all
astrocytes are equivalent in respect to their therapeutic value, and
this appears to be the first study demonstrating functional
differences between different human astrocyte populations with
respect to repairing the adult central nervous system. It is also
interesting to note the similarity between the outcomes obtained
with human cells and with our prior studies on rat cells [14,57]. In
a similar fashion to that observed for rodent GDAs transplanted
hGDAs
BMP were more supportive of axon growth than
hGDAs
CNTF at sites of spinal cord injury. Like the human
GDAs
BMP, rodent derived GDAs
BMP promote robust functional
recovery, while GDAs
CNTF did not [57]. The conservation of the
phenotypic and functional properties of GDAs
BMP and
GDAs
CNTF between human astrocytes and rat astrocytes suggests
that such properties are fundamental to the biology of these cells.
The one difference observed in these studies was that hGDA
BMP
transplantation showed a slightly longer delay (7 days versus 3
days) in providing significant behavioral recovery. Whether this is
due to differences in cell properties or a consequence of the
xenograft itself remains to be investigated.
It was also of interest to observe that prolonged survival of the
grafted astrocytes was not required to obtain durable improve-
ments in behavior and neuronal survival. This also demonstrates a
conservation of outcomes between human cells and rat cells, which
also did not require prolonged survival to provide durable benefit
[14,57], suggesting that this too might be a conserved aspect of
GDA
BMP function.
Figure 3. GFAP expression by transplanted hGDAs within DLF transection injuries. Images of hMito+ (red) and GFAP (green) immuno-
reactivity within hGDAs
BMP (A, C, E, F) and hGDAs
CNTF (B, D, G, H) transplants at the center of injury sites showing comparable densities of GFAP+
intermediate filaments (green) within hMito immuno-positive cell bodies and process of both types of hGDAs. Arrowheads indicate some examples
of GFAP+/hMito+ hGDA cell bodies at low and high magnification. Images are maximum projections of apotome (Zeiss) optical sections captured
through a depth of 3.5 mm of tissue. Survival=5 weeks post injury/transplantation. All scale bars=20 mm.
doi:10.1371/journal.pone.0017328.g003
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transplanted astrocytes (rodent or human) have been shown to
promote extensive neuroprotection of spinal cord neurons
following spinal cord injury, an observation consistent with the
robust neuroprotective effects of intra-spinal rodent GDA
BMP
transplants on axotomized neurons of the red nucleus [14,57].
While future studies will reveal whether transplantation of
hGDAs
BMP to DLF injuries provide protection of red nucleus
neurons, hGDAs
BMP provided robust neuron protection in
multiple spinal cord laminae, even in more distant gray matter
in which there was no evidence of hGDAs
BMP migration.
hGDAs
BMP were able to promote survival of multiple neuronal
populations within multiple gray matter laminae with notably
robust increases of up to 69% in neuronal survival in laminae 8
and 9 containing motor neurons. In contrast, although SCI rats
that were treated with hGPCs and hGDAs
CNTF showed positive
trends in neuron protection for laminae 8 and 9, this did not
translate to improvements in grid-walk performance and these
cells failed to promote statistically significant increases in neuronal
survival even in laminae into which they had migrated.
The underlying mechanisms accounting for why hGDAs
BMP
are so much more beneficial in terms of neuroprotection and
functional recovery than either hGDAs
CNTF or undifferentiated
precursor cells when transplanted into spinal cord injured rats
remain to be investigated, but it is likely that multiple cellular
functions are involved. For example, hGDAs
BMP express higher
levels of such astrocyte-related genes as glutamate transporter 1,
connexin 43, and AKAP12, which are relevant to maintaining
tissue homeostasis in the CNS as well as reducing astrogliosis and
neuronal death after injury, mediating glutamate uptake and
promoting blood-brain barrier formation [23,24,58–61]. These
and other differences between hGDAs
BMP and undifferentiated
hGPCs and hGDAs
CNTF, such as the marked differences in
expression of axon growth inhibitory CSPGs and the expression of
GDNF, may all contribute to creating a particularly effective cell
type for promoting functional recovery in the traumatically injured
adult central nervous system.
In brief our present studies provide the first demonstration of
the utility of human astrocyte transplantation as a therapy for
central nervous system injuries. Moreover, our studies provide a
specific population of human astrocytes that appear to be
particularly suitable for further development towards clinical
applications.
Materials and Methods
Ethics Statement
The University of Rochester RSRB has reviewed this study and
determined that based on federal (45 CFR 46.102) and University
criteria, the study does not qualify as human subjects research and
has waived the need for consent (RSRB#00024759). All animal
procedures were performed under guidelines of the National
Institutes of Health and approved by the Institutional Animal Care
and Utilization Committee (IACUC) of University of Colorado
Denver, Aurora, CO (UCAR# 80710(05)1E). or the IACUC of
Figure 4. Migration and morphology of hGDAsBMP within DLF
white matter. (A, B) High power images showing hMito+ hGDAs
BMP in
the process of migrating and accumulating at the pial surface within
lateral funniculus white matter. Note the elongated radially orientated
processes displayed by some hMito+ hGDAs
BMP within white matter (B:
arrowheads), a glial morphology indicative of tangential migration of
these cells towards the adjacent pial surface (hMito: red; NF+ axons:
green). (C) hGDAs
BMP displaying typical astrocytic ‘‘stellate’’ arrange-
ments of their processes within white matter immediately ventral to the
injury site. Survival=5 weeks post injury/transplantation. Scale bars: A,
B=100 mm; C=20 mm.
doi:10.1371/journal.pone.0017328.g004
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2008-075).
Preparation of human cells
Human spinal cord tissues were obtained from two nine week
old, de-identified abortus samples collected in the course of
medically prescribed procedures using the Safe-Harbor Method.
Spinal cord-derived glial precursors were grown and isolated as
previously described [62–64]. Spinal cord tissue was dissected
from the rostral neural tube of two 9 week old samples (referred to
here as 9W1 and 9W2). After removal of the meninges, tissue was
digested at 37uC with 59 U/ml papain (Worthington) in Hanks
balanced salt solution (HBSS, Invitrogen) supplemented with
10 mM Hepes (EMD), pH 8.0 and 125 U/ml Dnase I (Sigma),
and triturated in 0.3%(w/v) BSA/HBSS (Sigma), 250 U/ml
Dnase I. A2B5
+PSA-NCAM
2 glial progenitor cells were isolated
by step-wise immunopurification using anti-PSA-NCAM and
A2B5-bound magnetic beads (Miltenyi). and cultured in 5% O2/
7% CO2 in Bottenstein-Sato F12 medium with 10 ng/ml human
recombinant basic fibroblast growth factor (Peprotech) on a
substrate of 1 mg/cm
2 fibronectin (Chemicon) and 0.5 mg/cm
2
laminin (Invitrogen). Differentiation of hGPCs was induced at
2500 cells/cm
2 by replacing bFGF with either 20 ng/ml BMP-4
(R&D) or 10 ng/ml CNTF (Peprotech) and allowed to differen-
tiate for 7 days prior to harvest.
RNA and protein expression analysis
Characterization of hGPC and hGDA cultures was performed
by reverse-transcriptase semi-quantitative polymerase chain reac-
tion (RT-QPCR), Western blot and immunofluorescent labeling as
previously described [7,65]. Multiplex QPCR reactions of RT
product were performed using FAM-labeled probes for aquaporin
4, S100b, CX43, GLT-1 and AKAP12, in combination with VIC-
labeled, primer limited GAPDH probe and Taqman mastermix
(all Applied Biosystems). DDCt analysis was performed using
Microsoft Excel software as previously described [66]. Indepen-
dent experiments were performed in triplicate and average fold
change expression normalized to expression in undifferentiated
hGPCs grown in bFGF. Western blot analysis of chondroitin
sulfate proteoglycans and Olig2 was performed as previously
described [57], using anti-phosphacan monoclonal (1:1000, 3F8,
Developmental Studies Hybridoma Bank), anti-CSPG4/NG2
monoclonal (1:2000, Chemicon), anti-Olig2 polyclonal (1:4000,
Chemicon) and anti-b-tubulin monoclonal antibody (1:1000,
Santa Cruz). Expression levels of phosphacan (320–340 kDa
band) NG2 (270–300 kDa band) and Olig2 (32 kDa band),
respectively, were normalized for each sample to b-tubulin
(52 kDa) expression. All Western blot experiments were conducted
in triplicate and results were compared using the Student’s t-test,
p,0.05. Immunofluorescent labeling was performed using anti-
Olig2 (1:4000, Chemicon) and anti-GFAP (1:400, Cell Signaling)
followed by fluorescently labeled, secondary anti-Ig antibodies
(Alexa 488 and 568 conjugates, Invitrogen) at a 1:2000 dilution.
Monochrome images of parallel samples were captured using
identical exposure times and gain settings, and merged as pseudo-
colored images.
Spinal cord injury model
Adult female Sprague Dawley rats (3 months old, Harlan) were
used in all in vivo spinal cord injury experiments and were
anesthetized by injection of a cocktail containing ketamine and
xylazine. Unilateral transections of the right-side dorso-lateral
funiculus (DLF) including the rubrospinal pathway were conduct-
ed at the C3/C4 intervertebral spinal cord level (Supplemental
Fig. S1A and S1B). The dorsal surface of the spinal cord was
exposed by opening the intervertebral space between the C3 and
C4 vertebrae. After opening the dura, a 1 mm deep transection
was made lateral to the midline using micro-scissors. To ensure
that the injury was complete and that the depth was uniformly
1 mm, a 30 gauge needle was again inserted into the transection
site to a depth of 1 mm and slowly passed through the medial to
lateral extent of the injury. The use of an inter-vertebral surgery
Figure 5. Human GDAs
BMP promote robust locomotor recovery but hGDAs
CNTF and hGPCs do not. Graphs show the average number of
mistakes per experimental group made during Grid walk testing of locomotor recovery at 1 day before injury to 28 days after injury. In two separate
experiments, hGDA
BMP transplanted animals (closed circles) performed significantly better than hGDA
CNTF (A) or hGPC (B) transplanted animals at all
time points from 7 to 28 days post injury/transplantation. Note that the performance of hGDA
CNTF or hGPC transplanted animals was not significantly
different from control injured rats at all time points (two-way repeated measures ANOVA, *p, 0.05).
doi:10.1371/journal.pone.0017328.g005
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dorsolateral funiculus results in highly consistent deficits in grid-
walk locomotor performance [14,57].
A total of 6 ml of hGDA
BMP, hGDA
CNTF or hGPC suspensions
(30,000 cells/ml; 180,000 cells total) per animal were acutely
transplanted into six different sites at the injury site on the right
side of the spinal cord: medial and lateral of the rostral and caudal
injury margins, and medial and lateral of the injury center
(Supplemental Fig. S1C). Control injured rats were injected with
6 ml HBSS. All control or cell transplanted rats were immune
suppressed. Rats in the 9W2 groups were given daily injections of
cyclosporine (1 mg/100 g body weight) beginning the day before
Figure 6. hGDA
BMP transplants promote protection of spinal cord neurons while hGDA
CNTF and hGPC transplants do not. Montaged
images of NeuN immuno-histochemistry at the C5 spinal level of normal (A) and untreated injured (control) spinal cords (B) show that the unilateral
DLF transection injury causes loss of NeuN+ neurons in multiple spinal cord laminae adjacent to the transected white matter. Transplantation of
hGDAs
BMP (C) promotes significant protection of neurons in laminae 7, 8, and 9 at the injury center. In contrast, transplantation of hGDAs
CNTF (D) or
hGPCs (E) did not promote significant levels of neuroprotection. (F) Schematic showing gray matter laminae at the C5 level of the rat spinal cord
(adapted from [39]). All scale bars=200 mm.
doi:10.1371/journal.pone.0017328.g006
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Due to a temporary unavailability of injectable cyclosporine, rats
in the 9W1 group were given a bolus injection of methyl
prednisolone (30 mg/kg body weight) 1 hour prior to injury/
transplantation.
Histology
At 5 weeks post-surgery animals were deeply anesthetized and
transcardially perfused with 0.1 M PBS followed by 4%
paraformaldehyde in 0.1M PBS. Dissected spinal cords were
cryosectioned and immunofluorescently labeled as previously
described [14,57]. The following primary antibodies were used:
mouse anti-GFAP (Sigma), rabbit polyclonal anti-GFAP (Sigma)
or goat anti GFAP (Lifespan Biosciences); mouse anti-NeuN
(Millipore); rabbit anti- 200 kD neurofilament (Serotec); mouse
anti-human mitochondrial antigen (Millipore). Alexa-488, Alexa-
594, and Alexa-647 conjugated secondary antibodies (Invitrogen)
were used to visualize primary antibody binding. All secondary
antibodies were pre-absorbed against rat serum. To control for
nonspecific secondary antibody binding, adjacent sections were
also processed as described above without primary antibodies.
Some sections were counterstained with DAPI to show nuclei.
Labeled sections were examined and imaged using a Zeiss 510
Meta confocal microscope. Antigen co-localization and cellular
associations were determined with Zeiss Confocal image analysis
software.
Quantification of axon growth into GDA treated injury
sites
The relative density of axons within the centers of hGDA
BMP or
hGDA
CNTF transplanted injury sites was determined by quantifying
neurofilament-immunoreactive pixels in 4 tissue sections per spinal
cord from 5 animals per experimental group. Images were captured
(Zeiss-Z1 microscope) of the right-side dorsolateral funiculus from
every sixth histological cross section (4 sections in total per spinal
cord) from tissue at injury centers. Using Image-J analysis software,
a 465 mm6465 mm square region of interest was drawn on each
image with the upper right corner located on the dorso-lateral outer
edge of the transplant mass such that the region of interest was
contained within injury sites/transplant parenchyma (Supplemental
Fig.S2). The area within the region of interest filled with NF+ pixels
was determined. The sum total of NF+ areas of each region of
interest per spinal cord was calculated, and then the average area
per experimental group was determined. A two-sample T-test was
applied to assess statistical significance (alpha=0.05).
Quantification of neuron survival
Neuronal survival within spinal cord gray matter was determined
using NeuN immuno-reactivity as a marker of surviving spinal cord
neurons after spinal cord injury [34]. To quantify surviving NeuN+
neurons, 15 sections per spinal cord at 5 weeks post injury were
sampled from a 1.8 mm length of spinal cord encompassing the injury
site. 5 spinal cords per experimental group were analyzed. Starting
Figure 7. hGDAs
BMP promote robust neuroprotection of spinal cord neurons but hGDAs
CNTF and hGPCs do not. (A) hGDA
BMP
transplantation led to significant increases in numbers of NeuN+ neurons counted in a 1.8mm length of spinal cord encompassing the injury site.
Graphs show percentage changes in numbers of NeuN+ neurons in laminae 4 to 9; laminae 4, 5, and 6; 7; and 8 and 9 in spinal cords from animals
that received transplants of 9W2 or 9W1 hGDAs
BMP, hGDAs
CNTF or hGPCs and untreated control injuries. (B) Analysis of neuron survival within laminae
immediately adjacent to the site of injury shows that hGDA
BMP transplantation promoted significant protection of neurons when all laminae were
considered (4 to 9), with the most robust increases in neuron numbers in intermediate (7) and ventral (8 and 9) gray matter laminae. Numbers of
NeuN+ neurons in spinal cords of rats transplanted with GDAs
CNTF or hGPCs were not significantly different from each other or untreated spinal cord
injuries. * ANOVA and Pairwise Multiple Comparison (Holm-Sidak), p,0.05. + t-test comparison with untreated spinal cord injuries, p,0.05.
doi:10.1371/journal.pone.0017328.g007
Table 1. Survival of NeuN
+ neurons 5 weeks post injury.
Transplant
Lam. 4 to 9
All sections
#
Lam. 4 to 9
Injury site
No Transplant 2374.25+/2352.84 909.0+/2237.02
9W2 hGDA
BMP 3313.75+/2238.51* 1204.25+/2138.88*
9W2 hGDA
CNTF 2548.5+/2175.44 906.0+/2103.94*
9W1 hGDA
BMP 3128.25+/2327.41* 1153.75+/2127.95*
9W1 hGPC 2578.2+/271.59 938.6+/2117.48
ANOVA p,0.001 p,0.05
doi:10.1371/journal.pone.0017328.t001
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section was imaged (Zeiss-Z1 microscope). Using AxioVision software
the gray matter was subdivided into 3 regions: laminae 4-6; lamina 7;
laminae 8–9. NeuN+ neurons were counted within each region per
section. The average number of neurons (+/2 one standard deviaton)
per total number of neurons was determined per region (tables 1 and
2). The percent change was calculated by dividing the average
number of neurons per group by the average number of neurons in
the injury control group. A second set of calculations was conducted
on 6 sections per spinal cord through 750 mm of tissue spanning the
injury center. One way ANOVA and Holm-Sidak multiple
comparisons post hoc tests were applied to determine statistical
significance (p,0.05). The power of these tests, with an alpha of 0.05,
was 0.996 when all sections are considered, and 0.702 when only the 6
sections spanning the injury center are considered.
Analysis of Locomotor Recovery
Behavioralanalysis of volitional foot placement was tested using a
grid-walk behavioraltest (Foot Misplacement Apparatus,Columbus
Instruments) as previously described [14,57]. Two weeks before
surgery, rats were trained to walk across a horizontal ladder and
those that consistently crossed without stopping were used in
experiments. Baseline gridwalk scores were obtained one day prior
to surgery and rats were randomly assigned into experimental
groups. One experiment included the following three groups: DLF
injury + media injection (n=8), DLF injury + 9W-1 hGPCs (n=8),
and DLFinjury + 9W-1 hGDAs
BMP (n=8).The second experiment
included DLF injury + media injection (n=6), DLF injury + 9W-2
hGDAs
CNTF (n=6) and DLF injury + 9W-2 hGDAs
BMP (n=7). At
3, 7, 10, 14, 21, and 28 days post-surgery, each rat was tested three
times and the number of mistakes from each trial was averaged to
generate a daily score for each animal. Two-way repeated measures
ANOVA and Holm-Sidak post hoc (p,0.05) were applied to assess
statistical significance using Sigma Stat 3.5 (Systat Software Inc.).
The power of these tests for each independent behavior study, with
an alpha of 0.05, was equal to 1.0.
Supporting Information
Figure S1 Schematic illustrations of the adult rat dorso-lateral
funiculus (DLF) transection spinal cord injury model and cell
injections at injury sites. Dorsal (A) and cross section (B) schematics
of the rat cervical spinal cord showing right side unilateral
transection injury (red shaded area) conducted at the level of the
C3/C4 intervertebral junction. (C) Injections (six in total) of either
hGDAs or hGPCs were made at sites if injury, two into injury
centers and two further injections each to rostral and caudal injury
margins respectively (black diamonds represent injection sites).
C3/C4, junction of the third and fourth cervical vertebrae; DLF,
dorsolateral funiculus; Cf, cuneate fasciculus; Gf, gracile fasciculus;
GM, gray matter. (Cross section schematic (B) adapted from Grant
and Koerber [39]).
(TIF)
Figure S2 Schematic illustration of neurofilament sampling
region at injury/transplantation sites. Image-J analysis software
has been used to draw a 465 mm6465 mm square region of
interest (ROI, white box) on a representative image of an NF
immuno-stained tissue section at the center of hGDA
CNTF treated
DLF injury site. The upper right corner of the ROI is located on
the dorso-lateral outer edge of the transplant mass such that that
the region of interest is contained within the injury site/transplant
mass. Scale bar=200 mm.
(TIF)
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